Milltrust International's Green Earth Ventures is a discretionary venture capital portfolio investing in pioneering real climate solution ventures across the Energy Transition, Clean-Tech, Energy Efficiency, Recycling Waste Streams, Crop and Animal Protection innovation, and Food Production Systems.
The Milltrust range of private funds (Future Health, Green Earth Ventures, Smart Proteins) serve as the building blocks for the British Innovation Fund II. Investors can invest on a stand-alone basis, or at the top level.
Stay tuned for more info.
BugEra improve the natural traits of the Black Soldier Fly (BSF) through genetic engineering – creating a Modified Black Soldier Fly (M-BSF). This allows BugEra to rapidly develop novel strains to deliver an array of safe and sustainable bi-products. Backed by global leader in the production of biofuel, BugEra's first strain is already delivering for the rapidly expanding biofuel industry, decarbonising transport sectors such as aviation and shipping.
Founded in 2021, Cody Genetics is an animal biotechnology company that applies gene-editing technology to benefit livestock farming. The company enables breeders to receive sperm/oocytes that not only will have a pre-determined sex, but that in turn will only produce gender-biased offspring through unassisted reproduction. The gene-editing technology offered by Cody dramatically improves animal welfare by preventing the culling of billions of animals and immensely reduces resource-use.
Roslin Technologies is a biotech company pioneering sustainable solutions to support the food and agriculture sectors. Its mission is to advance disruptive innovations to improve how we produce proteins to feed the world’s increasing population. Its primary focus is on animal stem cells – and their huge potential as ingredients for supporting the global cultivated meat market..
Polymateria provides a tailored biodegradable solution for conventional plastic packaging, aiming to stem the global plastic pollution endemic. In 2020, the privately owned company was the first to achieve certified biodegradation of the most commonly-littered forms of plastic packaging in real-world conditions, in less than a year without creating microplastics.
Green Bioactives, a University of Edinburgh start-up, have developed innovative strategies to produce plant-derived natural products utilising plant cell culture with full freedom to operate. These technologies can significantly improve the yields of target natural products in cultured plant cells. This technology platform can be employed to produce high quality natural product ingredients for the cosmetic, pharmaceutical, food and agricultural industries.
Cambridge-based PragmatIC is a world leader in ultra-low-cost flexible electronics. Their flexible integrated circuits (FlexICs) are thinner than a human hair and can be invisibly embedded in objects, enabling innovators to create novel solutions to everyday problems that are not practical with conventional electronics.
CorePower is a UK-based development company, specializing in scalable atomic power technology for ocean transport and heavy industry. In partnership with leading international corporations, CorePower aims to deliver durable zero-emission energy for floating industrial production and deep-sea shipping.
The Smart Protein Fund is a joint venture between Milltrust International (Investment Manager) and Earth First Food Ventures (Investment Advisor) to invest exclusively in the Smart Protein sector.
The purpose of the fund is to disrupt the world’s largest industry -Food- by channelling climate capital towards the scaling of the Smart Protein sector for a cleaner, healthier end-product, produced locally for local consumption, with a significantly lower carbon footprint and lower GHG emissions, while at the same time providing attractive returns in a fast-growing industry with innovative technologies.
More information coming soon.
MyDoc is Asia’s leading telemedicine service company. MyDoc’s fully integrated online-to-offline platform streamlines all aspects of primary healthcare into one easy-to-use solution connecting patients to doctors, pharmacies, diagnostic laboratories, clinical-grade health trackers, Fortune 500 and SME employers, and insurers.
Eupnoos is an AI enhanced smartphone app able to use sound to objectively measure lung function in patients diagnosed with chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and interstitial lung disease (ILD).
Cambridge medtech start-up 52 North Health has developed an innovative device, Neutrocheck, that rapidly identifies chemotherapy patients at risk of a life-threatening complication called neutropenic sepsis. Through improving triaging, Neutrocheck has the potential to save thousands of lives, free up valuable healthcare resources, and make patients' lives easier, simpler, and better.
Jiva.ai is an AI company that uses a model fusion first approach to machine learning to provide a sophisticated platform that enables multi-modal AI, allowing non-technical users to iteratively grow, evolve and deploy models based on their data for real-world use.
Attomarker, a spin-out company from the University of Exeter, has produced a unique COVID-19 triple antibody testing device, giving a real-time analysis of immunity levels. The blood sample analysis tracks both the waning immunity from vaccines and ‘natural immunity’ boosts from COVID infections. The data it generates amounts to a personal COVID-risk profile for each individual.
Singapore-based Safe Space offers a comprehensive online and offline mental health solution using therapy sessions and other resources. Using this system, patients and therapists can connect quickly, and patients can access therapy from anywhere in the world. The Safe Space platform strengthens mental resilience by providing quality, affordable tele-therapy care and prevention education.
Oncoshot is a health insights exchange platform that leverages its proprietary clinical trial matching artificial intelligence (AI) technology to address the inefficiencies of cancer clinical trials. The platform serves as a bridge between leading regional healthcare institutions and contract research organizations (CROs) and global biotechnology and pharmaceutical companies to facilitate data-driven cancer clinical trials while accelerating enrolment into actively recruiting ones.
Viome is a health testing company that uses artificial intelligence (AI) to analyze an individual’s gut biology to gain insights into their health. The service offers personalized food recommendations and made-to-order supplements according to these test results.
Vaccitech is a biotechnology company developing vaccines and immunotherapies for infectious diseases, specialising in T-cell immunotherapy. Having developed the Oxford/AstraZeneca vaccine and administering over 2bn doses globally, the company was listed on NASDAQ in 2021, reaching a peak valuation of $628m.Exit
Totient is an artificial intelligence-driven drug discovery platform that identifies and harnesses human-derived antibodies from individuals with exceptional immune responses. Totient was acquired by Absci for an undisclosed amount in 2021.Exit
AMLo Biosciences is translating ground-breaking research in cancer biomarkers into a revolutionary range of prognostic and companion diagnostic products to improve patient outcomes and reduce the financial burden of cancers on global healthcare economies.